<SEC-DOCUMENT>0000856982-25-000006.txt : 20250128
<SEC-HEADER>0000856982-25-000006.hdr.sgml : 20250128
<ACCEPTANCE-DATETIME>20250128163548
ACCESSION NUMBER:		0000856982-25-000006
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250128
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250128
DATE AS OF CHANGE:		20250128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MERIT MEDICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000856982
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870447695
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-18592
		FILM NUMBER:		25564750

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST MERIT PARK WAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		8012531600

	MAIL ADDRESS:	
		STREET 1:		1600 WEST MERIT PARKWAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mmsi-20250128x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 1/28/2025 9:31:56 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: 3e14a7b8-8bfb-4a34-b7d4-081a8ba9cf43 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mmsi="http://www.meritmedical.com/20250128" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:EntityCentralIndexKey" id="Tc_nvoRRgXpgEy9jmXAypduIg_2_1">0000856982</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:AmendmentFlag" id="Tc_IF9CFnGolU-jlU32RNW96w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mmsi-20250128.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000856982</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-28</xbrli:startDate><xbrli:endDate>2025-01-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:50.24pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_6a7d01a3_db3f_4a1a_bcba_6952adefcd3c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:DocumentType" id="Narr_soQSottoR0ywKjGlbytDLQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_BQ4ghzdqoU-SbpfIxBck7g"><span style="font-size:9pt;">January 28, 2025</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mmsi-20250128x8k001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;width:279.71pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:EntityRegistrantName" id="Narr_l4AwACUGqkCLsHKA5uD2mg"><b style="font-weight:bold;">Merit Medical Systems,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_482e885a_2d52_4623_b7e4_21eef4425b9e"></a><a id="Tc_W5FR6LUKFEOoYufAb2ZJiw_2_0"></a><a id="Tc_kWFV6H-1-kCxl0OHDDXlqQ_2_2"></a><a id="Tc_ElfLYN4JzE24uC_Mo88y3g_2_4"></a><a id="Tc_m44ix5_ySEefV1RmvFLEwQ_3_0"></a><a id="Tc_k_6fJz5XF0K67GkM25fvkA_3_2"></a><a id="Tc_3krDXwxa7EWqN5uaLe3K0w_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_tpFWV0CW_kK4Mc6EDLeoyA_1_0"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:EntityFileNumber" id="Tc_MDTHDnDJ4Em7xHbRr_kGUQ_1_2"><b style="font-size:9pt;font-weight:bold;">0-18592</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:EntityTaxIdentificationNumber" id="Tc_QUOou8kY_UKUzwnJE9omfA_1_4"><b style="font-size:9pt;font-weight:bold;">87-0447695</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer</p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">incorporation or organization)</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_7d471683_06d1_45fe_9287_288340eace6c"></a><a id="Tc_ztwSqzvNsUWr5eCNcuuC1w_2_0"></a><a id="Tc_eRnwBekOHUeOxqbwFV90Qg_3_0"></a><a id="Tc_98AqoVwrJk6ZdopFSnMG7Q_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:EntityAddressAddressLine1" id="Tc_GE8qBfpS-kiG60qhrpaMJA_1_0"><b style="font-size:9pt;font-weight:bold;">1600 West Merit Parkway</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:EntityAddressCityOrTown" id="Narr_-hI3iWWUwECPmJ_NxHZvkg"><b style="font-size:9pt;font-weight:bold;">South Jordan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_4fGy4SPMN0maZ9y0RuZqJA"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:EntityAddressPostalZipCode" id="Tc_yY3dMSpAHECuwfJcoZYzWg_2_2"><b style="font-size:9pt;font-weight:bold;">84095</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:CityAreaCode" id="Narr_I8uFZLCOTEGp6dvcUgs0Fw"><b style="font-size:9pt;font-weight:bold;">801</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:LocalPhoneNumber" id="Narr_zjYW2HYe2kaon0qYT8f4rQ"><b style="font-size:9pt;font-weight:bold;">253-1600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant's telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_IMV3MKtn5EmfSh8Ibk5CkQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_azpgOUHTdECEt0lMRjcfYA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_tEdplloxdU6KCwmgb4fyJA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_PayPD_ALdEOed67ODqvUTg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_e1adca4e_7a42_4339_9783_775404ac1f0f"></a><a id="Tc_I5PS_HIjS0apu6NmEJdpJQ_1_0"></a><a id="Tc_cgeeiM_af025uDLDtkR0-w_1_2"></a><a id="Tc_AMBcEhTO30WuYmZZxvmwcg_1_4"></a><a id="Tc_nUkv4lfxXkG-BjPVogY7Mw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Title&#160;of&#160;each&#160;class</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Trading&#160;Symbol(s)</p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</p></td></tr><tr><td style="vertical-align:top;width:31.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:Security12bTitle" id="Tc_9J3X4NcKP0CpSjMwj-YE9g_2_0"><span style="font-size:9pt;">Common Stock, no par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:TradingSymbol" id="Tc_treu-9EBaUOlF0Ppi6bRAw_2_2"><span style="font-size:9pt;">MMSI</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" name="dei:SecurityExchangeName" id="Narr_m62SUmRUn0KBfHej8fMFmA"><span style="font-size:9pt;">NASDAQ</span></ix:nonNumeric><span style="font-size:9pt;"> Global Select Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_EvQDkj3Z2U25CwoH3ne6wA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a7242462_aaaa_4182_971f_493daf3b12ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 28, 2025, Merit Medical Systems, Inc. (&#8220;Merit&#8221;) is conducting a conference call to discuss commercial, marketing and industry updates related to its WRAPSODY&#8482; Cell-Impermeable Endoprosthesis (the &#8220;Wrapsody CIE&#8221;). In connection with the conference call, Merit released the prepared remarks to be delivered during the conference call, a copy of which is furnished as Exhibit 99.1 to this report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information contained in this Item 7.01 of this Current Report on Form 8-K (including the exhibit attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Current Report and the exhibit hereto contain forward-looking statements about Merit that involve substantial risks and uncertainties. Merit intends such statements, and all subsequent forward-looking statements attributable to Merit, to be expressly qualified in their entirety by these cautionary statements and covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and Section 27A of the Securities Act. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;objective&#8221; or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. However, not all forward-looking statements contain such identifying words. All statements included in this Current Report and the exhibit hereto, other than statements of historical fact, are forward-looking statements for purposes of the Exchange Act and the Securities Act, including any projections of revenues or other financial items, statements regarding plans, objectives or development of existing or future products (including, without limitation, the Wrapsody CIE), statements concerning the prospective markets, reimbursement practices, anticipated regulatory approvals or commercial opportunities for existing or future products (including, without limitation, the Wrapsody CIE), statements regarding future economic conditions or performance, and statements of assumptions underlying any of the foregoing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merit&#8217;s actual results, levels of activity, performance or achievement to be materially different from those expressed or implied by these forward-looking statements, including those risks, uncertainties and other factors described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and Merit&#8217;s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024, and September 30, 2024 and subsequent filings with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All forward-looking statements included in this Current Report and the exhibit hereto speak only as of the date made, are based on information available to Merit as of such date, and are subject to change. Merit assumes no obligation to update or revise any forward-looking statement. If Merit does update or correct one or more forward-looking statements, readers should not conclude that Merit will make additional updates or corrections. Merit&#8217;s actual results will likely differ, and may differ materially, from anticipated results. Readers should not unduly rely on any such forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0c74a69b_cfac_4e80_8149_d8a437ccccfb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:34.5pt;"><td style="vertical-align:bottom;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;NUMBER</b></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION</b></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">99.1</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mmsi-20250128xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Conference Call Remarks.</span></a></p></td></tr><tr style="height:15.4pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">104</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_e41c4e77_278c_4866_b318_093099dab7df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.8%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MERIT MEDICAL SYSTEMS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 28, 2025</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;">/s/ Brian G. Lloyd</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;border-top:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian G. Lloyd</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal Officer and Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mmsi-20250128xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 1/28/2025 09:31:53 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-size:11pt;"><a name="_Hlk54257290"></a></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merit Medical Systems Wrapsody Investor Conference Call Remarks</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operator: </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-size:11pt;"><a name="_Hlk529444201"></a></font><font style="font-family:'Times New Roman','Times','serif';">Please standby. Welcome to the Merit Medical Systems Wrapsody Investor Conference Call. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the Company&#8217;s website for replay shortly.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I would now like to turn the call over to Mr. Fred Lampropoulos, Merit Medical Systems&#8217; founder, Chairman and Chief Executive Officer. Please go ahead, sir. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fred Lampropoulos: </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, operator and welcome everyone. I am joined on the call today by multiple members of the Merit team, including:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">John Hall, our Executive Vice President of R&amp;D, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Caleb Konstanski, our Vice President of Sales and Marketing for the Renal Therapies Group, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raul Parra, our Chief Financial Officer &amp; Treasurer, and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Brian Lloyd, our Chief Legal Officer and Corporate Secretary. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I am also pleased to welcome Dr. Danny Patel, the medical director for interventional nephrology at the Volusia-Flagler Vascular Center in Daytona Beach, Florida and a paid consultant to Merit.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dr. Patel has graciously agreed to participate today and share his valuable insights and experiences related to stent-graft use in dialysis access. This has been an area of clinical interest for him during his more than 15-year career as a practicing interventional nephrologist.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Before we begin, Brian, would you mind taking us through the Safe Harbor statements, please? </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brian Lloyd: </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thanks Fred. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I would like to remind everyone that this presentation contains forward-looking statements that receive safe harbor protection under federal securities laws. Although we believe these forward-looking statements are based upon reasonable assumptions, they are subject to risks and uncertainties. The realization of any of these risks or uncertainties, as well as extraordinary events or transactions impacting our company, could cause actual results to differ materially from the expectations and projections expressed or implied by our forward-looking statements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition, any forward-looking statements represent our views only as of today, January 28, 2025, and should not be relied upon as representing our views as of any other date. We specifically disclaim any obligation to update such statements, except as required by applicable law. Please refer to discussions entitled &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in our filings with the SEC for important information regarding such statements. For a discussion of factors that could cause actual results to differ from these forward-looking statements, please also refer to our most recent filings with the SEC, which are available on our website.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I will now turn the call back to Fred.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fred Lampropoulos:</u><u style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, Brian. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Let me start with a brief agenda of what we will cover during our prepared remarks: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Before diving-in on the WRAPSODY</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">TM</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Cell-Impermeable Endoprosthesis, or &#8220;CIE&#8221;, I wanted to start with a brief history of what started as a &#8216;big idea&#8217; in 2010, to help investors appreciate that Wrapsody CIE is really &#8216;just the beginning&#8217;. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">After my opening remarks, John Hall will discuss the key design and development features of the Wrapsody CIE and then we will hear a clinician&#8217;s perspective with respect to the device from Dr. Patel.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Then Caleb will provide an overview of the estimated addressable market for the Wrapsody CIE and our U.S. commercial strategy. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raul will then talk about key financial and non-financial milestones for our U.S. Wrapsody CIE program for 2025. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Then we will open the call for your questions. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As we announced via press release on December 20</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';">, the WRAPSODY Cell-Impermeable Endoprosthesis received premarket approval from the FDA. We received orders shortly thereafter and were pleased to hear clinicians began using the device to treat patients in the U.S. in early-January. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By securing premarket approval and initiating the U.S. commercial launch of this novel therapeutic technology, we are pleased to have achieved two important milestones for Merit. These accomplishments are the result of many years of hard work and dedication to a strategic initiative that started as a &#8220;big idea&#8221; back in 2010. Importantly, we believe the achievement of these Wrapsody CIE milestones should not be viewed as the culmination, but rather, more likely represent the </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">first</u><font style="font-family:'Times New Roman','Times','serif';"> of what we believe will be a series of outcomes of multi-year strategic initiatives. We look forward to leveraging the impressive foundation for future therapeutic product innovation that we have built as part of this strategic initiative in the years to come.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Looking back to early-2010, the genesis of this strategic initiative was an evaluation that we undertook of Merit&#8217;s business and competitive position in the MedTech industry. At that time, we had grown our business to approximately $260 million in annual revenue. Merit was viewed as a trusted manufacturer of products serving key markets&#8230; and as a company that had strong customer relationships, primarily with hospital administrators and cath-lab supervisors. We realized that in order to fuel the Company&#8217;s next stage of growth, we needed to transition the business towards developing higher-value, more therapeutic, medical devices, which we believed would strengthen our relationships with physician customers. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With this &#8220;big idea&#8221; in mind, I set out to build a team to lead this effort. John Hall was my first hire for this strategic initiative; he had significant experience leading the product development at medical device companies. John built a team of experts with skills that were largely unique to Merit. Together, they identified multiple areas with attractive market potential, unmet clinical needs, and the opportunity for Merit to compete. We ultimately chose &#8216;dialysis outflow circuits&#8217; as the initial market on which to focus our development efforts. John will share more color on what led to this choice and the genesis of the Wrapsody CIE product specifically &#8211; in a few moments&#8230; but I want to share a brief history of this important strategic initiative to help the investment community appreciate that we have been planting the seeds of potential future therapeutic product development for many years now. We have allocated capital to organic investments, not just in the product development, but also in the manufacturing and supply chain. We </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">believed it was imperative that we continue to invest in a vertically integrated infrastructure to facilitate the long-term foundation for future growth. To that end, as part of this strategic initiative, we also directed investments to establish, or enhance, our capabilities in additional areas, including Clinical Affairs, Marketing, Reimbursement, Regulatory and intellectual property protection.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Clearly, these important organic investments were intended to support our growth of our global medical device business over the last 10 to 15 years&#8230; but they were also a direct result of our strategic initiative to transition the business to developing higher-value devices, that are more therapeutic in nature, and more effectively meet the needs of physicians.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We have also allocated capital to in-organic opportunities as part of this strategic initiative. In 2012, we acquired assets from Medigroup, adding peritoneal dialysis catheters to our existing offering of chronic dialysis catheters, guide wires and access devices. In 2016, we acquired the HeRO</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';"> Graft hemodialysis access system, further enhanced our dialysis portfolio, and our presence with both vascular surgeons and interventional radiologists. Finally, in 2023, we acquired a portfolio of dialysis catheter products from AngioDynamics and the&#160;</font><font style="font-family:'Times New Roman','Times','serif';">Surfacer</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;Inside-Out</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;Access Catheter System</font><font style="font-family:'Times New Roman','Times','serif';">&#160;from Bluegrass Vascular Technologies.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">These in-organic investments were made with three clear goals in mind: </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">broaden our therapeutic platform, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthen our commercial position in the dialysis market, and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our specialty dialysis device offering. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As a result of these investments, our Renal Therapies Group is now armed with a broad portfolio of interventional solutions, strong physician relationships and a focused commercial infrastructure. We believe we are well-positioned to increase our share of the global dialysis market in the years to come. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I am proud of the team&#8217;s strong execution and commitment to this strategic initiative, and we are excited to see the initial fruits of this labor as we introduce the Wrapsody CIE to the U.S. market this year. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">While the U.S. commercial launch of the Wrapsody CIE represents an important inflection point in our company&#8217;s history, I hope the investment community now has a better appreciation for our strong belief that the Wrapsody CIE should not be viewed as the culmination, but rather, as I have said before, more likely represents the </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">first</u><font style="font-family:'Times New Roman','Times','serif';"> of what we believe will be a series of outcomes of this multi-year strategic initiative.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I would like to turn the call over to John Hall, who will discuss the Wrapsody CIE in more detail&#8230; John? </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">John Hall: </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, Fred. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Wrapsody CIE project was inspired, in part, by feedback from a physician who approached Merit about an unmet clinical need for dialysis patients with stenosis in the outflow circuit. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The physician was frustrated with the significant challenges associated with existing covered stent grafts on the market. As an engineer, I embraced the opportunity to evaluate actual patient cases where then-existing covered stent devices were not effective. Looking at human tissue explants and histological analyses of failed covered stent grafts, we identified numerous examples where stent grafts kinked and occluded, fractured, developed tissue on the lumen, or experienced &#8216;edge&#8217; stenosis and restenosis.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our evaluation of failed covered stent grafts revealed that not only were the existing products not preventing restenosis, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">in the vessel,</u><font style="font-family:'Times New Roman','Times','serif';"> as intended, but our evaluation also revealed something we found really, really interesting. Specifically, the histological analyses highlighted that there was tissue growing </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">through</u><font style="font-family:'Times New Roman','Times','serif';"> the ePTFE graft covering. That was a key determinant in identifying the first of four innovative features upon which our technology would be based. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Let me take a moment to discuss these four features, all of which we believe represent significant advances versus the existing alternatives in the market&#8230; and, most importantly, we believe will result in improving patient outcomes. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The first innovative feature was a stent graft design that could actually prevent tissue from growing </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">through</u><font style="font-family:'Times New Roman','Times','serif';"> the graft. The Wrapsody CIE has a complete internal cell impermeable layer to prevent luminal tissue proliferation. The Wrapsody CIE is not &#8220;just another covered stent&#8221;, it is truly a cell impermeable endoprosthesis designed to stop transmural cell growth.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The second innovative feature was focused on addressing another key driver of failed stent grafts: thrombosis. We pursued a concept of modifying biocompatible PTFE to reduce fibrin and thrombus formation, without the use of heparin and drugs like the existing alternatives on the market. We took the same polymer that was commonly used in stent grafts, &#8220;ePTFE&#8221;, and created a new microstructure using a proprietary spinning process that resulted in a more random microstructure, mimicking the architecture of blood vessels; it ended up resembling the random nature of a bowl of linguine. Our differentiated technology was initially validated clinically in our animal studies, which demonstrated that this novel microstructure reduced fibrin deposition and thrombus formation. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The third innovative feature was designed to manage the challenges related to mechanical forces and radial forces present in the anatomy of dialysis patients. The Wrapsody CIE has optimized compression resistance and outward radial force&#8230; along with softer end-rows to help manage the transition back into the healthy vessel more naturally.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The fourth innovative feature is that the Wrapsody CIE technology is packaged into an elegant catheter delivery system. We developed a ratcheted deployment handle for one-handed, accurate, and controlled endoprosthesis placement&#8230; a handle that really allows the clinician to land the device with a high-level of precision. The delivery system also features a hydrophilic coating, which enables smooth endoprosthesis insertion and withdrawal through the delivery sheath and exceptional trackability through tortuous vasculature.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our development efforts were initially validated in bench and animal testing, but we were really excited by the strong clinical results from our prospective, observational first in human study, </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">&#8220;WRAPSODY FIRST&#8221;</i><font style="font-family:'Times New Roman','Times','serif';">, where the Wrapsody CIE delivered 84.6% target lesion primary patency at 12-months and 65.9% access circuit primary patency at 12-months. We were even more excited by the 6-month clinical results from the randomized arteriovenous, or &#8220;AV&#8221; fistula arm and AV graft arm of our </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">&#8220;WRAPSODY WAVE STUDY&#8221;</i><font style="font-family:'Times New Roman','Times','serif';"> pivotal trial announced in September 2024. Clinical results like those reported in these pivotal trials, reflect changes in patient lives, period. Less time in the chair, less time and risk from reinterventions and an overall improvement in quality of life for patients. Patients are not the only ones who benefit from the improvements offered by the Wrapsody CIE. Less time treating existing patients means clinicians can treat additional patients suffering from this disease and fewer interventions offers the potential for significant cost savings for our healthcare system. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The clinical validation supporting our Wrapsody CIE is impressive. We have studied 423 patients in the U.S. and international markets in our &#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">WRAPSODY FIRST</i><font style="font-family:'Times New Roman','Times','serif';">&#8221; and &#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">WRAPSODY WAVE STUDY</i><font style="font-family:'Times New Roman','Times','serif';">&#8221; clinical trials, demonstrating safety and significantly stronger efficacy versus the standard of care. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We intend to enroll up to 500 patients in a post-market study, currently underway, called, </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">&#8220;WRAP OUS GLOBAL </i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">REGISTRY&#8221;</i><font style="font-family:'Times New Roman','Times','serif';"> and will be initiating a new post-market study of up to 250 patients in the U.S. and Canada, called </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">&#8220;WRAP North America Registry,&#8221;</i><font style="font-family:'Times New Roman','Times','serif';"> in June of this year. We believe this impressive body of clinical evidence &#8211; evaluating the safety and efficacy of our Wrapsody CIE across a global patient population of nearly 1,200 patients &#8211; represents not only an invaluable tool in our discussions with physicians, hospital administrators and payers, but also a key differentiator versus the existing competitors. Ultimately, we believe this robust body of evidence will clearly demonstrate how the Wrapsody CIE can improve patient lives. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fred Lampropoulos:</u><u style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thanks John.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I would now like to introduce Dr. Daniel Patel who has agreed to spend a few minutes with us today to share a clinician&#8217;s perspective, insights and experiences related to stent-graft use in dialysis access and feedback on the Wrapsody CIE.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dr. Patel is an interventional nephrologist who is board certified in internal medicine with subspecialty certification in nephrology. His clinical interests include stent-graft use in dialysis access, intravascular ultrasound, and central venous stenosis. He founded the Volusia-Flagler Vascular Center in Daytona Beach, Florida in 2010, and still currently practices there.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dr. Patel has presented his work at more than 60 conferences and symposia including the Charing Cross International Symposium in London, the Vascular Access Intervention Therapy meeting in Japan and the annual meeting of the American Society of Diagnostic and Interventional Nephrology. In addition, he has published extensively and is an editorial board member for The Journal of Vascular Access and has reviewed more than 30 manuscripts for publication.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dr. Patel has received several awards for teaching, research, and ethics. An active industry consultant, he serves on the medical advisory board and as a trainer and lecturer internationally for several medical technology companies and is a fellow of the American Society of Diagnostic and Interventional Nephrology&#8230; Dr. Patel?</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dr. Danny Patel:</u><u style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, Fred. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I appreciate the opportunity to join in today&#8217;s discussion on the Wrapsody CIE. Merit asked me to discuss a few topics including my background, profile of my practice, general patient pathway and treatment in the dialysis access market today, my views on key differentiators of the Wrapsody and key factors that may impact adoption of this novel technology.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I am Medical Director of Volusia-Flagler Vascular Center in Daytona Beach. I have been fully dedicated to dialysis access since founding the practice in 2010. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In the interest of full disclosure, I am currently serving in the first year of a contracted relationship as a consultant for Merit focused on training new users.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">My practice is 100% outpatient dialysis access. We are transitioning from an office-based lab to an ambulatory surgery center in 2025, but functionally, it is a single-site practice in the outpatient setting, fully focused on dialysis access for hemodialysis patients.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Procedure mix includes dialysis access angiography, stent placement, coiling of accessory branches, tunneled catheter placements and exchanges, as well as vascular mapping, and percutaneous fistula creation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We are considered a higher-volume practice &#8211; with a high percentage of patients receiving dialysis access stent-grafts.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In terms of patient pathway: patients are followed clinically and referred from the dialysis units. Angioplasty is usually the first line treatment for clinically significant AV access lesions. The typical pathway involves assessment of the success of angioplasty. Immediate recoil or rupture generally calls for a stent-graft placement. Short term recurrence may also call for stent placement. Most AV access studies show a 6-month angioplasty patency rate between 20-50%.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Clinicians do vary in their management of recurrent stenosis. Some choose repeated angioplasty, some chose drug-coated balloons - which are cost-prohibitive in outpatient settings &#8211; others may chose stents or stent-grafts.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We generally choose to place stent-grafts if there is recurrence within 90 days or development of complete access thrombosis. However, the choice of stent-graft placement is also contingent on the clinical significance of the stenosis and the location of the lesion. Some anatomical lesions tend to respond better to stent-graft placement as primary treatment, versus angioplasty alone &#8211; and this is being supported more and more in the literature.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to my views on Wrapsody, and I&#8217;ll note for consideration that I was not an investigator in the clinical study and have only been using the device for several weeks. These views represent only my initial thoughts and opinions as a new adopter of the technology.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The biggest differentiation of the Wrapsody over other devices is the cell-impermeable membrane. The other leading stent-graft devices on the market lack this layer. However, the clinical advantages in routine practices of this membrane are still unknown in routine clinical practice.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Wrapsody is fairly easy to use, and the deployment is similar to other stent-graft devices on the market &#8211; which does allow for a minimal learning curve to use.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The existing initial clinical data is strong, and longer-term studies could add further support to the efficacy of the device. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I believe the biggest challenge of widespread adoption of Wrapsody will be the pricing of the device compared to competitors. Additionally, a large percentage of dialysis access management in the United States is in the outpatient setting &#8211; where choice of device use is extremely price sensitive. Pricing strategies of the Wrapsody and its competitors may strongly influence outpatient adoption. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Another limitation is the larger diameter sheaths necessary to use the Wrapsody, compared to its competitors. Some clinicians may not feel as comfortable using the larger sheath sizes, compared to market competitors. I don&#8217;t believe more experienced clinicians will be as concerned by the sheath size; however, the learning curve may be there for others.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Wrapsody has some potential to become a first-line treatment at specific locations over angioplasty, given strong outcomes. However, the competing stent-grafts on the market have also been used as first line treatments over angioplasty as well. Further usage and adoption of the device will give clinicians more experience of stent-graft usage and outcomes will influence uptake of the device. Another potential limitation is the absence of clinical use in treatment across the elbow joints. It&#8217;s unknown how much this may impact adoption of the product over time.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fred Lampropoulos:</u><u style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, Dr. Patel. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I would like to turn the call over to Caleb Konstanski, our Vice President, Sales and Marketing of the Renal Therapies Group to provide a high-level overview of both the addressable market opportunity for the Wrapsody CIE and our U.S. commercial strategy&#8230; Caleb?</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Caleb Konstanski:</u><u style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, Fred. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Beginning with an overview of the &#8220;dialysis access maintenance&#8221; market&#8230;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">From a patient incidence perspective, data from the &#8220;2024 Annual Data Report&#8221; from the NIH US Renal Data System reported for the year-ended 2022, indicated that more than 660,000 people in the U.S. were living with End Stage Renal Diseases, 84% of which &#8211; or nearly 560,000 &#8211; were undergoing in-center hemodialysis.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This is an important number from our perspective because these patients have undergone a dialysis access </font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">creation</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> procedure to enable the dialysis treatment&#8230;.and are candidates to receive a dialysis access </font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">maintenance</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> procedure, or procedures, given the complications related to access and outflow circuits that patients on dialysis face. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Of the nearly 560,000 U.S. patients undergoing in-center hemodialysis, approximately 331,000, or 69%, are using an AV fistula for access and approximately 91,000, or 16%, are using an AV graft for access. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Combined, we believe there are more than 420,000 U.S. patients, undergoing in-center hemodialysis with an AV fistula or AV graft. We believe this represents the </font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">total</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> addressable patient population in the U.S. for the Wrapsody CIE, based on the indications for use in our PMA approval. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We believe Clarivate provides good data on the current market for &#8220;dialysis access maintenance&#8221; in the U.S. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">According to Clarivate&#8217;s &#8220;Dialysis Access Treatment Devices - Market Insights US Report&#8221;, published in September 2024, there were 665,000 dialysis access maintenance </font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">procedures</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in 2023, 654,000, or 98%, of which were endovascular. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">77% of these endovascular access maintenance procedures were &#8220;plain old balloon angioplasty&#8221;, or &#8220;POBA&#8221;, procedures. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The remaining 23% of these endovascular access maintenance procedures were comprised of stents, thrombectomy or combinations of both. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:90pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Importantly, Clarivate reports there were 95,000 stent units implanted for dialysis access maintenance in 2023. Merit views this as the </font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">initial addressable market</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> opportunity in the U.S. for the Wrapsody CIE.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to our U.S. commercial strategy&#8230;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As Fred mentioned earlier, we began taking orders shortly after our PMA approval in late-December and we were pleased to see that customers began treating patients earlier this month. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As discussed on our October 30, 2024 earnings call, the plan for U.S. commercialization of the Wrapsody CIE, post-PMA approval, was part of a broader, comprehensive, commercial strategy for our Renal Therapies Group. &#8220;RTG&#8221; is an experienced, dedicated, team of sales and clinical partners offering a strong portfolio of dialysis products that address the entire end-stage renal disease continuum of care&#8230; including our HeRO Graft, our Surfacer Inside-Out Access Catheter System and our portfolio of acute, chronic and peritoneal dialysis catheters. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As we moved through 2024, our Renal Therapies Group was understandably excited to add the Wrapsody CIE to our dialysis product offering following PMA approval and we were increasingly focused on ensuring we would be ready to enter the U.S. market following PMA approval.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The team completed intensive Wrapsody CIE training covering a range of important areas including: the technical &#8220;story,&#8221; anatomy, physiology and deployment technique. Clinical data trainings and live, hands-on trainings were also conducted. Sales team readiness activities were bolstered by the rollout of a comprehensive marketing plan to support the U.S. launch. The early successes we are seeing to-date are due in part to this thoughtful, multi-channel, marketing approach focused on raising awareness through social media postings, partnership channels and advertising in both digital and print. As well as strong physician relationships and clinical partnerships that have been cultivated over the last 12-18 months supporting the current RTG product offerings.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The sales team has a targeted plan to engage with new and existing customers and is working through the VAC approval processes across the country. We&#39;re working with the largest group purchasing organizations in the U.S. to get this product loaded into their systems including HPG, Vizient and Ascension among others, as well as some of the largest IDNs across the country including Atrium, MUSC, University of Texas, and the VA. We believe these efforts will help drive the adoption of the Wrapsody CIE. These processes vary by facility and can take a differing amount of time. We have a strong support team with our strategic accounts, marketing, and product management that are supporting the different requests that come through the VAC process and we believe that we will be able to get the Wrapsody CIE approved in key hospitals around the country in a timely fashion.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Regarding physician awareness and engagement specifically, we plan to host physician training events at Centers of Excellence. These Merit-branded events will be led by a group of physicians that will work as our &#8216;clinical experts&#8217; serving in a valuable peer-to-peer role. The RTG team will be running in-service intros to physicians in their respective regions as well. All-in, we project our efforts to result in more than 250 active physician advocates of the Wrapsody CIE by the end of 2025, a number that we believe will grow over time, as we continue to identify physician partners who are passionate about the product and educating their peers on the benefits of the Wrapsody CIE.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Importantly, while RTG&#8217;s U.S. commercial strategy is focused on the launch of Wrapsody CIE, the total strategy is comprehensive; with the team out planting seeds and working the process for Wrapsody CIE conversion. We continue to open new doors and identify opportunities to drive adoption and utilization of the rest of our dialysis product portfolio. We are very pleased to see early evidence that this strategy is working; the team is adding new HeRO and peritoneal dialysis accounts, and we are seeing a notable up-tick in new customer conversion for our dialysis catheter offering including the BioFlo DuraMax</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';"> Catheter, Acute Hemodialysis Catheters and Centros</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';"> Hemodialysis Catheter.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to pricing, we believe the Wrapsody CIE is a completely new treatment option for patients as evidenced by our Breakthrough Designation from the FDA. Therefore, as part of our go to market strategy, we intend to sell Wrapsody at a premium price relative to the competitive covered stents offered in the U.S. today. The Wrapsody CIE is a novel, differentiated product that improves dialysis maintenance procedure outcomes as demonstrated in the compelling body of clinical evidence evaluating safety and efficacy to-date and we offer unique size offerings with our 14 and 16mm devices that represent potential treatment options for clinicians previously not available in the marketplace. The data suggest that Wrapsody CIE requires fewer reinterventions to maintain patency at the lesion site and, more importantly, that the access circuit remains functional&#8212;which is key for any dialysis patient. Our pricing strategy for the Wrapsody CIE is aligned with our long-term reimbursement strategy for securing add-on reimbursement payment in the hospital and office-based sites-of-care. We believe the Wrapsody CIE offers a compelling opportunity to not only improve patient outcomes, but also to reduce the cost of treating this patient population. These factors, together with demonstrated clinical outcomes and the fact that the Wrapsody CIE is the only device that has been designed specifically for dialysis access maintenance, supports our belief that the Wrapsody CIE should be a premium product in the market. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We know that the economics within a hospital, outpatient/ASC, and OBL are very different and with that we have </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">created pricing strategies that align with our NTAP and TPT reimbursement strategies, but also are not a financial burden to the facilities that are treating these patients. Under the current reimbursement for covered stents in the dialysis circuit we believe that our pricing strategy aligns with our long-term goals, but also short-term is not a financial burden for these facilities and we&#8217;ve created a pricing program to best work with our customers and their individualized financial situations. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fred Lampropoulos:</u><u style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, Caleb. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I would like to turn the call over to Raul Parra&#8230; Raul?</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Raul Parra:</u><u style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thank you, Fred.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">I wanted to provide updates on our progress in a few key areas of our Wrapsody CIE program, specifically: </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursement, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical validation and raising awareness of the compelling safety and efficacy profile of Wrapsody CIE among clinicians and,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2025 revenue expectations for Wrapsody CIE in the U.S. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Beginning with reimbursement&#8230;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The team has continued to execute on our reimbursement strategy for the Wrapsody CIE since our last update to the investment community. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By way of reminder, on October 7th, we submitted our application requesting a New Technology APC assignment for Medicare&#8217;s Acute Inpatient prospective payment system. The New Technology Add-On Payment, or &#8220;NTAP&#8221; designation enables new medical service or technology meeting certain eligibility criteria to receive additional reimbursement payment for a period of up to three years. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We believe that the Wrapsody CIE meets the eligibility criteria, particularly as it relates to the requirement that the technology represents an advance that substantially improves, relative to technologies previously available, the treatment of Medicare beneficiaries. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We notified CMS that we received PMA approval in December and our application for NTAP remains under review. We continue to expect to hear CMS&#8217;s decision in June 2025, pursuant to their stated timeline for the NTAP program. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We are also pursuing add-on reimbursement for the Wrapsody CIE in the office-based site of care, or &#8220;OBL&#8221;. The OBL add-on reimbursement process is different than NTAP in a few ways; most notably, it is a 90-day application assessment period and companies can only submit applications once PMA approval is secured. As a reminder, for office-based add-on reimbursement, we are applying for &#8220;Transitional Pass-Through Payment&#8221;, or &#8220;TPT&#8221;, under the Medicare hospital outpatient prospective payment system, or &#8220;OPPS&#8221;. The TPT program is intended to facilitate access for Medicare beneficiaries to the advantages of new and innovative devices by allowing for adequate payment for these new devices while the requisite cost data is collected. We believe the Wrapsody CIE meets the &#8216;substantial clinical improvement&#8217; threshold for new category eligibility for a pass-through payment. We are targeting submission of our application by the March 1, 2025, deadline and, anticipate receiving a decision with respect to the award of </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">pass-through status in June 2025. If we are awarded pass-thru status, the Wrapsody CIE would be eligible for add-on reimbursement as early as Q3&#8217;25, which we believe would continue for at least two years thereafter.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We intend to update the investment community with any material progress in our efforts to secure NTAP and TPT add-on reimbursement.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to clinical validation and our efforts to raise awareness of the compelling safety and efficacy profile of the Wrapsody CIE among clinicians&#8230; simply stated, we project a steady stream of progress in the areas throughout 2025.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We believe the Wrapsody CIE will be featured in presentations at multiple medical meetings and industry events in 2025. That said, there are four meetings that I would like to call special attention to: </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">First, the Society of Interventional Radiology &#8211; March 28</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to April 2</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">nd</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; in Nashville, TN.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Rajan is scheduled to present the 12-month AVF data from our WRAPSODY WAVE trial on Sunday, March 30 at 3:27pm as a Late Breaking session.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Second, the American Society of Diagnostic and Interventional Nephrology, or &#8220;ASDIN&#8221; meeting &#8211; Feb 7</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to 9</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; in Grapevine, TX.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Bala is scheduled to present 6-month reintervention rates data from our WRAPSODY WAVE trial.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Third, the Charing Cross meeting, April 23</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">rd</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> - 25</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; in the U.K.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Rob Jones is scheduled to present the 12-month AVG data from our WRAPSODY WAVE trial on Wednesday, April 23 during the &#8220;Access Revision&#8221; session.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">And fourth, the Society of Vascular Surgeons Vascular Annual Meeting&#8211; June 4</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to June 7</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; in New Orleans, LA.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Dexter is scheduled to present 12-month reintervention rates data from our WRAPSODY WAVE trial.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition to the Wrapsody CIE being featured at medical meetings, we believe there will be multiple publications featuring the device&#8217;s safety and efficacy. We intend to update the Street if these publications become available this year.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Turning to a discussion of our 2025 revenue expectations for the Wrapsody CIE in the U.S&#8230;.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Historically, Merit has not provided revenue disclosure for specific products &#8211; on a reported-basis or forward-looking expectations. That said, given the unique nature of the Wrapsody CIE, specifically, being the Company&#8217;s first PMA approved product and the related multi-pronged reimbursement strategy, we have elected to provide forward-looking revenue forecast for U.S. Wrapsody CIE revenue in 2025. Although we are providing this forecast in this unique situation, we expressly disclaim any obligation to update or disclose revisions to this forecast or to provide similar forecasts in the future.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">To that end, for the full year 2025 period, we forecast U.S. revenue from the sales of the Wrapsody CIE in the range of $7 million to $9 million. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition to this forecasted revenue guidance range for sales of the Wrapsody CIE in the U.S., we would like to offer the following information for consideration when evaluating forecasted guidance:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">First, as discussed earlier, we are pursuing a multi-pronged strategy to secure add-on reimbursement payments for the Wrapsody CIE in the hospital and office-based sites-of-care. We currently expect to receive </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decisions on both NTAP and TPT add-on payments in June 2025. Note, our full year 2025 revenue range reflects multiple potential scenarios and assumptions for adoption, utilization and commercial strategies that are influenced by the outcome of each add-on reimbursement process. We continue to believe that we meet the requirements to secure both NTAP and TPT add-on reimbursement payments. That said, until we have secured those add-on payments, there is a level of related uncertainty.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For avoidance of doubt, we have not deviated from our core philosophy on providing forward-looking financial expectations over the past four years; the investment community should appreciate that we continue to provide forward-looking financial expectations, in a range, where the low-end of the range reflects a realistic view of what we expect to deliver if we execute our plan. While nothing is certain, we believe we have a high-level of confidence in our team&#8217;s ability to deliver at least the low-end of the range of guidance.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Second, for modeling purposes, our full year 2025 U.S. Wrapsody CIE revenue range assumes a larger weighting of revenue in the second half of 2025 vs. the first half, and a larger weighting of revenue in the fourth quarter vs. the third quarter. These assumptions are driven primarily by the mid-year timing expectation for add-on reimbursement payments in the hospital and office-based sites-of-care. We are also sensitive to the potential impact on adoption and utilization as we navigate the VAC-approval process. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Third, and finally, we do not intend to provide incremental financial, or material non-financial details on our U.S. Wrapsody CIE commercial strategy given the potential competitive impact in the marketplace. For avoidance of doubt, while we intend to provide updated expectations for U.S. Wrapsody CIE revenue on each of our quarterly earnings calls this year, we do not plan to disclose revenue results on a quarterly basis.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With that, I&#8217;ll turn the call back to Fred for closing remarks&#8230; Fred?</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mmsi-20250128x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20250128x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# 74# 2(  A$! Q$!_\0
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M/V@/AI874MM<>/?#T4\3%70ZC%E2.HZU#_PT7\+O^B@>'?\ P8Q_XU/MJ?\
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M1D]C7VOKWPK\)ZSX#N?"<V@V*:"ULT*6D<"JL0VX#)@?*PZAASGFN _9'^"
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M^6,>6^_^>GW7WU\CT(U:*PKKUZOMO9M.-T]&T[0?,M;OWG'6*4&D_>.T\%?
M7P-X&T\P6F@6E_>2_-=:IJD2W5Y=N?O/+*X+,2>?3T K@OC-\/M-^$&G7'Q3
M\"V$/A[5]$*7.JV6G((;;5K$,!/%-$N%+A"75\;@R]>:9\=/C+JVC?%CX?\
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MK],_V!_^3<M,_P"PA>_^CC7YF3$-/*0<@NQ!'?DU^F?[ _\ R;EIG_80O?\
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M'5$@V[?+%SC=TXS][WSS5WPQ^U]\4_"'@N+PQI^OQ_88(O(M[FXMEENK>/&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mmsi-20250128.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/28/2025 9:32:02 PM-->
<!--Modified on: 1/28/2025 9:32:02 PM-->
<xsd:schema targetNamespace="http://www.meritmedical.com/20250128" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mmsi="http://www.meritmedical.com/20250128" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:rxp="http://xbrl.sec.gov/rxp/2024q3" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:cyd-8k-sub="http://xbrl.sec.gov/cyd-8k-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20250128_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20250128_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mmsi-20250128_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/28/2025 9:32:02 PM-->
<!--Modified on: 1/28/2025 9:32:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mmsi-20250128_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/28/2025 9:32:02 PM-->
<!--Modified on: 1/28/2025 9:32:02 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mmsi-20250128.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638736967225062851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638736967225062851" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638736967225072883" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638736967225072883" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638736967225072883" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638736967225072883" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638736967225072883" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638736967225072883" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638736967225072883" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638736967225072883" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638736967225072883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638736967225072883" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638736967225083242" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638736967225083242" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638736967225083242" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638736967225083242" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638736967225083242" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638736967225083242" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638736967225083242" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638736967225083242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638736967225083242" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638736967225093324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638736967225093324" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638736967225093324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638736967225093324" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638736967225093324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638736967225093324" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638736967225093324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638736967225093324" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45897845780320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 28,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-18592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merit Medical Systems,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0447695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West Merit Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Jordan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">253-1600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MMSI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000856982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( '>$/%H'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ =X0\6JOM .[O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ =X0\6IE<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !WA#Q:
M&*/^A$P$  "T$   &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ =X0\6I^@&_"Q @  X@P   T
M     ( !D P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !WA#Q:EXJ[',
M   3 @  "P              @ %L#P  7W)E;',O+G)E;'-02P$"% ,4
M" !WA#Q:'#AEZC\!   \ @  #P              @ %5$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ =X0\6B0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M=X0\6F60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mmsi-20250128x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mmsi-20250128.xsd</File>
    <File>mmsi-20250128_lab.xml</File>
    <File>mmsi-20250128_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="mmsi-20250128x8k.htm">mmsi-20250128x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mmsi-20250128x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mmsi-20250128x8k.htm": {
   "nsprefix": "mmsi",
   "nsuri": "http://www.meritmedical.com/20250128",
   "dts": {
    "schema": {
     "local": [
      "mmsi-20250128.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mmsi-20250128_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mmsi-20250128_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mmsi-20250128x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20250128x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20250128x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000856982-25-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000856982-25-000006-xbrl.zip
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M?(G@HD#[7'LS-+],66M=5A[?V\?_;%%_A[)WVN#='T,^_@U02P,$%     @
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MR<3_X). F<S%\1*;#WB;@)(U0U05A (? 'X3F?U;=H#]ZI[4LYW*FVZ0_7@
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MYPUHT)CIN'R#%5XY/(0A\A,5H-4P  <4>T=OR4]9GMO< <$YP 2F"&AD6.%
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M91 !!SKT)2^TKQ^<<$ $!(^KF.$K1@(XY$'BD1F;10QA"L(=U0F/4/17\*;
M<7PSB$]K'_WY=^U,NQF\[\:WO?GM29RH<O]S./CI]U1/_'L')XG?[OUG.XVA
M.DA(HT#?.$X"HPES-&B6@7EWQX\PQQW8VOND:<[LG(?_4>:#2I^P3;H?H5&:
M_S0V9&#""&-;="432R^T(@H?=W=<9TO0PS(:ZCX;"+B#%,HU"8'"._GE)SH$
MH!7EF]<"N-_7-=5'A^("1N5<MPDCYD)!F [%N68+LZ*%]>-_:EQ\O)Q7+9]W
M4+.'5E2@ATUGP&Y,<:\PP[UB=8.@Y4'L=%1&A>2#!A/GSI[Q0'[M7E!,XFE<
M\,5 B4R/Z+'<%TJ ,:S5(QS-XD9@QZ\Q,<\[<73<CA05?K<Y'4OA:@OP"%L^
M=QRK_3SO$F\:E!/)0\=;1LX+NL;[)W'43NK5UI%!.SJC.R1?X.]&[NE(56$H
MLQVLH!M>H]C'H'VULMQ'8O9.Q<YSRE2[!6.^T?=G;,]-=$SW&'Q9"/,J-+YH
M+*3[7/:0,E-M>>Z4?1O.!Q+=@' 2@6=N'CT@_K?E.QF[%2O5OK13-44#&ODW
M8<LWPI1NA"^T.HU];2ZB37<&Q?F %.4'<,?"D=W/OMM^S+:&9OR6T1LSG+)1
M=&^7"O47_R8* -3WJ?5>H6X2@9P/1""$MO&I;(GU%1EZ7"P_$;A;U0Z2)TPB
MF$"<L+7SKC.+;CO9'G\5[[\6C9)L"CBAIE]Q<+_>]S\IL+*)0Q))J:)#4J;I
MXCH3:\II@E>ML^D5^*92)G*2C&OB&CT,W(,5EY@XMT%D.(;*UJ5Y;3L)LX:G
MHW_N>S;!?9$ZIB.EB]'GIB<?\;/2O=(S2$T<0TS65?DX0SH^$Q2'$F.8YAW(
M7GJ<H6KI]:H8-<?*3DP"!Y2[MS+#H\ &/:_KS9\-)7S[<V^H=_$U*'Q#Q:+9
M)5-R+?F<8E-V7E"'OV"9U=^5I\W^26(D?V^!H\WCSP7<'XVT,U9?*:FPERUZ
M^CY-U3*1*#HV:/H[6U8Y->Z]KAEA^QD Z[D,\GQD'_VP0U-YN*C59@'G"::D
MP EA=2M0@KWBD1:F-W[>P.K4A[XES'0PC_@@9OO[.!4";V<Y>WWPJ'&2%-2Q
M_=/#R$4?KU1:$.GK/)0/O]KAW'.W_QX^F**T66508F&JK:*^'GP7*R[HR:B<
M"-[/L_!9Y#&IH7C.\[Z3&C$D<?**P+X?D=K-Q."T]/;GK:X["1=^973O8&6S
MJ#Y>K9[O2^NZALFYZB=^]14KY[F*H4C0S7:\W?F=K04A7) 1=.E<(B9FCN(S
M,Q%XB6IB"9]=_</L+XDTMB_ ZBR]M>/8[R7(CDM6MGEBHA11X7;_"$.5LBX-
MDCB&)J+5O]W?FOOPC5_.&!>^+)6Q^.E-<E<'\]UME1/J7^I+:[]'3FZ^?NDP
M_AX9>+)UIL*6EAA8LM$>B$CK7PMER')<53:LL4V]QY2CZQ./2QA>#KF<"NYW
M6.:1GB4"EOC^KYL<03N2TG*S/@),W5T=>2%7+WO$05MMW[A*EC2\[3.P68LY
M&8L(>D%H@[GU>DP]AV++0K6W>XVNK\^Z]]*G:RRZJ)@1\7B)E#$0PY]M>+U.
M=+!OF2"I-)Q'K2K378G UEK[N<)T$]*;6_E^R'-W3/M:--O>7-*H0OH"$5AJ
M5W\X>*\ZUH&6M:V82\^C=25Z%6&C^NLT>=KRTW)G"_4E<#1\09%P(3&$<)*^
M&@QJP!M@>!#7G,_<LRGKRY/F[+6N:7HR_#1YYL1WWT'JLO7!@2&U<B4YQF)G
M$,/$<?$$I_C!<:SM9M7,5IR[V[A]&R+:QH%7@D>4V>%UK^Z^I9\ PRZ(8OO,
MZ(/:*RRR2V8#ZL\F8CM2N5<)T4W](^2MRS"D/3CPI86W4J.DU,1 Z3>''7J]
M<<MO$9OB*&Y6^JQ(;..OX^\L/Z-41=6%LV#)QII P0(\>9[!\CX_+-D*_]:!
MHPP3QVDP>C0S1;AWHU;:D?=PQ_RG18"0\/OKBXQA[1@/&OR+U\E.+0_G1^W'
MI.#W[(.P,01]G;[A<UIG])D&^]/@)UC^MSB>DU2L7S+&3HK/T8#_^L0KCL-U
MIX^V-F^Z*;S(6?#C47N;3I5[4QT-=WLAUQ-64_[<*.TSCVY/^EKTO#*-$.+N
MSR]\F0WB@97\30]E(M$,*1;RM?M$]=/P:9JEWW=PG.<I=]4'Q"N>.2OYP9?[
M?0+T(JF2*Y/RO*""+[4*$\Z%Y*<G*Q_I$MMEK@H]X9?&6P1A%75:<?!NGEUM
M&KDZ17\"2VM;TEH?89;JA>6[B,SK#\+,/BY^)*/@/M[(TL;G+CYYJ848D;]4
M4D#RZE.,'@G.6U=H[Q8VOVPE$6202Y]%W&=QZXGO]P,_%P@;Q,:NP\KF"085
MI%HXNBI &RQ8<*%)D@@]" Y8LE']M*^^7:@;;6\5QJJ@KC92*;I0[T?$GZ&!
M'J^>*?.8*CS\)!"?BM,>$=BIHK#>-.<^V&S8TM/PE1UD+6ISS$LM2*!IXU1S
ME-N?"==K'0GEP[?J(W+TLP;!O?Y37@9B_>"4:NVK8"WVU"J8''[Z9#E2]:MT
MP29(H&Y*I![LY;R<]KSAC^J.LQ6R)7K-XN3).ON^XM\_)R^_X&;:) ,:M9EM
MW)R4;%)=LV9!Z<<J%=)+Y@A<M:DMODQ^,"U9^?!.&^6+UZ,V-LB+V\<CD3G/
ME"4^1L,ZJQZ-=;#C935K;-3!7=;"V=]B:?+&\\V0B/[!9Q<N^+>E,!&-<=<V
M=0\&=$RP1G"F>2+[4'!A1N?+S$=>)G(67M1V7_PK7<9/;+"$(FI4L$,%/J9/
MY2)<UL5?I;WWN\7^2B_=MW\*OI,GF-KIB<MXO@O(-2<"PY!6QYY4YZD"[J;H
MH50%M-"-JH9=;9SYQ@I:+OO4N08=BWBY3[N0<9Q+2Y(>--0QM[2#0J#=^/KN
MMS\RY7N\OH8>M'R./9!(A,=UW,*AN\!1?BJLO<5X(H T#GB $5Y(8T8F^@>R
MD?3WVP/RR4*-03<7..!K61?3+G6(68]F_;%@PY,-6LV#OJ4"P09Q$#F=QAN'
MGY^[EY#&9;39KH5<:',(&HWO[X[K8MLCQ_+[_WF#D?QR)'M7)M<M)S4FMOFO
M([_-/B$P9!H-$1R)LY:@W9XNVVW/,E0TTAZO$Y"9VE_PG!+3*+Q<KL-:_("0
MPWB,[EH[<:2?)EU,6W\MO39O;]=\/GRGDNZ>2*[1?8DP_"#VW "O46P;;(J5
M? ?BGSQZD*Y2D?8YC,?-NN<N:Z^<?H04<[I%WV+_=.8KI%%L2T,<SG&)I "#
M%65[*LIG=#%T)6]N202LWNMVU]UX<4M;L'*"O_Y/Z%@!N/:T!W).9@_?^%J6
M7ILBPB7A10C54:>.+_K0;=XSX66&:G%K[6V5%YZML$C-W/"&<W1<WR+(3RU.
MR]F=IC7Z?7<[5Q_K5)/F'G+L5J2ZK4CVZ0H7UT2\H<48B;\NRUWVS#7C4BBJ
M%NU,9XX)%GH#H2JQ>+7#:L5=V^4(7L94_TXDB&5D^%+I7^)DJGX[/UNT-$BK
M54W-4*%"3Y].PJMS$VW 3M#08K/06,V5A'=J(5:BG"$G_.%$X)]!R.?4,T4B
M0,E!!)+XBN S@4R7K/+!-[%9G1^#M?#92W!Z.UL>&P,3@FI D6DDR_%3Q"XS
M#?^*Q>^75_M97TPACZ+()^/H(R9S1KT]1EV&B$"7 8D2%HNKZ)B9O_;W<"E>
MFYDT!%5U-5[;^?C%YAXGV#$OJ_TD$: XQ?-*2;F'"KLT$('F\)"TZ'@ER=.7
MGT.4XXS."9,8[NSXBG,#PBC=%\NYAF2G9/A+&VM'ND+GAIXJP89)BEP+5W_V
ML[@E.(/S CUV+2MO4V';^:OSU*8;A2;>6)LJQ,@K*,G YZF3>+TR8<#O,(0(
M5 EV80:F8+RLW?:3.- 1$6AE2 G=504'7!:$7Q809#JQFDNA>954.I/KI,B,
M[:()UK;?577Y)N]+A:3S]0:;G5\+YL[%('K.$ZY#?Y^V:$=YGI0*-_WMF"VY
MM_!EO7(LN.]T=ML,#$5SXJ.6179Y2'5EEEI>N&E!<CLPZ/EUX63G@/='K@E9
M-3= ]:?H3D0D-[QS/TH%''&$J:&S/+6U?1ONJ>HM5+PUB_P"^%6,G:V)[R]&
MK<%J4V"0&[$WB #JGMXN$;@C23#:]Z@&]R ^6'MTJTL8MG1<[O85E=HX^_EU
M?A\WD'M+I9["X;WSM:4UX?@:$6B"IX:&A(Y"6.0]^$)G^5FQW9IRYB"^J7*W
MG1VLO]Z^D(DN2'7E*?GEQ*G\V56?3LFO+V\^$;QFI-$;R 8]=QZ4+"C^F\N3
M^0(\^\E6:.7RK-HK5'<N-01UUM B\'Z<-"/TH(]'$1E5X^ 9 8)!_R,B\#UB
MGQ O_S?C'H-:(6_8C@;?7_FS5_]%'[7QUI)F$^D#\"L<.>$?T@K "Q<3^$>U
M_.'0#@O;M0$DP+@RO4J]:X#+ZY"_,&]'U*<@HH[^S&Q"9PM,#_6/$R/A\S2J
M%JC<1D@O#SH*00VN]1G#V>.3O+]FI2K=T_Q>UP0J+_ 8_; +R>K@P9+"%N-[
MJ?A@[,:Y=E&)85K#2'S$S.*K$<;"$R!S8V"[6?=QPO"1FA3PVT$OY3"0X +2
M#3:Y5&?=^^=,?2503J5VKF9SW%:]W#NWY2"_3"7!EMJ6"+2)9X=XG+M<*(P3
M6"ZD\%I+;DI4T<C=+BM<N-K ]PPAT$Y/KL-;5 <$&Q4A+\T'*];#GB1R9I=N
M^=.Y7<EYD]ROF%_2S[K!$,#NK&*FGH4VZA4H7LTH4D-2'J\6\J01@?[K\OX'
M%B'1WLZ*:6=FE47"K45Q$S6:% ,@*W[UUA_'<^W>QQ6(*#"C/#J:(!;3W<$;
MQI-M;IGS/#[@G9X9('G(KSH]0@0:.=_($8&(!7Z\P5*(F-%,W3;=SW?OO"7V
MWK5%77Y]9GD)76>BP&_;X3TQ-,?##%M,15O5?3C)W[>4:;OI[_Z(]]PT])GD
M;DO>A&8L5A_+VK9NP_3%]+/2,T_&#+1:H:.*CK.L)XSXGJ$O&V?65SR;ZQ]B
MU8>HH'\(0L$<\+?@[]/O+]2]8>EGGZ<?VR\,T]P"R^_=Y#%5VS4SNZ[^VI#*
M$Z(([W:X<"0">1A2Z9%)(O#SS_#(DT1\,HZ\N]&:\[V:*:BH<-Y-UD:]350
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MKN:<N]08.\US3GVL8E3Q75A!GVE#EH=,R+;J8UE_7R+@BAD"HWS*<V?UNT]
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M&68ILS)@FEUKB9\WV7/ZV6F>XOUS\2.9VN%@(.)"]54O$3A2WH#CZ13QHT2
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M#5N-2;VQ[,Z!!TIW ,?M_UU(Y(+H/5Z=$H%.ZDQLLHOAD[WLZ2;2ZP^CCV\
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MHP J+<IBV'Y"RX*Q4QA.T+<DW"%NXI1)I6=\!5)N/3'WQ'S+<MK;%S!JVLP
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M>X,$O!38XY%.("<DUXQ/H88F;'ISX[Q<J"2KDB:K \BD,V?E!>1^<22'1&Q
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M"BZA4C+D*3'SD-2W#4 IT5:C3FT'SNA*VJ:&1.-TZ:2""!=F>W!H;P=L&YO
MAZVGF_@DLU?4CD4RG<DZN2"B2H6"D%_)@:);M_VL*3FD&)GNVG)9O[8I!8WR
ML@17 G1TGI=+=K:)X])<H*A*G(F6\)M.D@8:P*G3$A6:.<R/%;MVGNN$T38"
M=_@[.@7*^@:]X M7].91@!DNRZ,?N1I\5U6-&-P0V):Y(.&9)+/!:E_9I40%
M0QR)OKQ,2:]/B9026K<68!#1;(8GL%ME9R4ZCE>VDA46'1!.=V$I::47\"#$
MT7$+]4\G_L5B,:>>9S)+N3? K2X$S&39?A'I+B2'7(\SEW'W'+Y%'/YZ,RB8
MQQ59-\9(?XT,ZERYZE_LL%IBU1+[!DJ]J8SG(%]8/5J*M>SP'7WFWX^_YM"!
M--B7?D;.0)4C@$AJ1Z(^9N$RHK#^EFV:(;NI*BEYN62=!R3R%Z=OS\Z=F?[]
M=]EU4<Y#9K@K-1V'TED]?;CS^%M5 [<.T&NLYP7Y<@DC@8Y_B<3PWOZ0#-YZ
M*N;&XT<[S[[U^ :N,.*#WV(QRZ\*<0<'FM)]6X_ETBM>5VOVLU4"D.<J(V.[
M((D1#RL[>N>Q",=DJI 802L*K_GHG8LQX0.''/,9WN=O1^]^5&?GOY[\ZZ9>
MJIIGER5#A50R4\3#\Q.UGI&,]6C\^P]W6B H?YC.]RQY\#U"M?(]"2%W;FR1
M(N*2<5BB;(9R-8Z$:T$^P$C%6TAWU$OV!FFEWN8$Z%LU $&YS]E*S:RKWJE,
MW 'DVGID#I"6&%%5.MQMNN&_&\VJ@OV[L>CAUH!]X\MWM"MMX/()^,,,RXWB
M()(B9DPD&D@I>H"5IK:6$&-&B7?&J/L9=X#XS*1_\LP L#_"[D^@NAFE/X+I
M"I?;QB.HN 4A]I59[D3"28P-L8KJGA O4JR#"!60#J)3FX(0O-4(K+?S9,2&
M3G ZWN;IU>H6J=7S8# 213CE"2GNT+G\?-K50&Z+@]Y"1$J0(U4/]Q]L'B\1
MT&8*KR@=VK*/ECCQ=PN"M:LAKRU%O9K CC[#HELU<&,K#^_<B^LV)H5W;O78
MU(+I%XD(DHIB%L$C'^.S9!DG_>#>IW#J@>VDJ\_4W-C+BL\'/B;5(UQ36,!=
M17R5?GFTN]MA>0!#V7KHV@F=_4ON+J*I#'"<FFJA\1FB5.EMV\;J]:]GZJ>7
MKY\?O53,07V5WKVMTOMS9'^#=/7VQY].S\[?WIQ%+K$0Z;2+YN](8F6-CR!;
MA>GV'^U>K6>/=:%3[1GLMOGKEQ*1MZ,979UH@,)BPL%R<&-'1+O[1U.8T',H
MO<F_Q?-V.D:)&I5R4D'-&4P+1>S9@WK[JC>/FMTJO*#9G)_7'16*Y R"8*['
MW[LT\W+>Y*%TL6!@5+4WV(\%HW]TU%D:*A?1;5OPDI WK,LR]T:1*]1A.[X[
M*H&T]H?F2LR1K[<1UK8K)(O26F3D;ZK9\>,\>!#%KP'N?67"$2:;E2.D\?UI
MAT-F<DX$'C;.=M%Z%^OQA$3[FA[3=1%[^^'.V0_WLL4/+6#JI0:)S<LF+^T!
ME]2$O5R_K_//[,P][EH[ZUL6[Q1W7,\3U\6%Y3[G+<M<K#'$5_ZF?<\\,#!\
MWWP+T')"ELT)ALCD"$[2?Q&#Y"*]265<>=O<")(15]X436V<:0!%7J9Z&<\C
M"8'% -(Q)Y4?,A=98;%MZ_)LOOFI4S; )4%#"8 W#.>D5G&*)?+H>BQ=$5(G
M%KI=)/V54S!H5(@S$Z"8+B)78>;3RH%(,_G25:,2@:$$^5]NY\N*MM24D?YI
M Z[DHQFU&'+N"VY^)^#S_;V7.^KGS+86ON]%L6Z4A?D(LATPW^D C-WD])N%
M]^^R\@9_SI6DBD+S'SW9-<2X?LMW9=[83 ]?Y'J2FZK%)SXV6!6>?**7-1V.
M>FYT,AVH%V0"9*GVDT3E<?2:8#>'.,F<YSB!&;E%IA\ ,/[J!P"TG >5X/Q(
MPQVV;N)M[:=.$%\^WD5A";M[OMC++F<(S>AHX L/$IQJSBD=LWM[VHG2G\E7
MFAFH]659I"A69;+W9.[@OT\C,># _62D!>X,'U[/M:];-'YZH_^[@Z-R081"
MG95)9B1O=Y+I"3$>D';QY=.NM/DED@BG[6B;@4QWHT-J>"@.*FO>$P-;F;3!
MR0CIHD[AZ2(C)C)J)CE09,"0'?D'.>%X#*UC=;_<VJRY&U%@I]J3?[#+,ZUL
M4F7S6M)IO X19#TG]YS<Y>0P]MWRP.%<:9G&R0,,H3*X; 7LCLIG41=HSDQ(
M&1T5RLW[\S-6P?5(V6O,:.(2^2HN#G>#=73*PT:7CN[#K%-2>702,F<^-VY@
M:B=QE\MX0+]6?\.HG"Y,0@R,1N8A:M1N@L]])5PXPO_>+NMR&QVF>QDX<KY8
ML10RZ\-&=Y!9MH WKATVVEZDJVT4A=>+'74FP:Y!_?Q>9C(% &&@$/%I<T@;
M8S,>],H".V=FXO9P"3+5Y1PCFUJ78;94;:8<T\[+,=!FT0K7NJT#'KE;Q5DR
M74\76HQOKG#S17J=H04NI.3!B+&3 >X+(YN-F/4TUOI47SP"UV&J;%FY!H 9
M/3LCPR1!:5TY]^FZJ/NJ-6'ZB-66\8W,KH.=>L*#($ON^?S4T,V.!P[FR<OC
M)N<,)^[K@J5K$]PR9$0Y6M0.$Q<&\=&?;1/:7SNM%0[W6@*2W%G<.,3;O+3<
MS<KTV$;ZX*"Y($F+YL*8RMR@RMU!FF?^QA,-E&O=][Y>-+,]:GMF=PXW1ST)
M?5CUD]*VBMQ>+2.!8A6JK]!=Z77NBCSBLAEDAMJVR5!+CB)Z%+^8(2,!88*
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MB=WM8J[?5NH4UJ0O*,R!\&R@+>E(SQAC% A;5G$U9.ZG7TG[ U=DMHV6 8=
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M,#(U,#$R."YX<V102P$"% ,4    " !WA#Q:D[[P=6H%  #N.P  %0
M        @ 'F P  ;6US:2TR,#(U,#$R.%]L86(N>&UL4$L! A0#%     @
M=X0\6C0!9O1]!   ^R4  !4              ( !@PD  &UM<VDM,C R-3 Q
M,CA?<')E+GAM;%!+ 0(4 Q0    ( '>$/%JTOMO<"1L  (O$   4
M      "  3,.  !M;7-I+3(P,C4P,3(X>#AK+FAT;5!+ 0(4 Q0    ( '>$
M/%K;_XO$=RL   LM   7              "  6XI  !M;7-I+3(P,C4P,3(X
M>#AK,# Q+FIP9U!+ 0(4 Q0    ( '>$/%KJM38,(4$  (#K 0 8
M      "  1I5  !M;7-I+3(P,C4P,3(X>&5X.3ED,2YH=&U02P4&      8
,!@"2 0  <98

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>mmsi-20250128x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mmsi-20250128.xsd" xlink:type="simple"/>
    <context id="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000856982</identifier>
        </entity>
        <period>
            <startDate>2025-01-28</startDate>
            <endDate>2025-01-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_nvoRRgXpgEy9jmXAypduIg_2_1">0000856982</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_IF9CFnGolU-jlU32RNW96w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_soQSottoR0ywKjGlbytDLQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_BQ4ghzdqoU-SbpfIxBck7g">2025-01-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_l4AwACUGqkCLsHKA5uD2mg">Merit Medical Systems,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_tpFWV0CW_kK4Mc6EDLeoyA_1_0">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_MDTHDnDJ4Em7xHbRr_kGUQ_1_2">0-18592</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_QUOou8kY_UKUzwnJE9omfA_1_4">87-0447695</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_GE8qBfpS-kiG60qhrpaMJA_1_0">1600 West Merit Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_-hI3iWWUwECPmJ_NxHZvkg">South Jordan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_4fGy4SPMN0maZ9y0RuZqJA">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_yY3dMSpAHECuwfJcoZYzWg_2_2">84095</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_I8uFZLCOTEGp6dvcUgs0Fw">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_zjYW2HYe2kaon0qYT8f4rQ">253-1600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_IMV3MKtn5EmfSh8Ibk5CkQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_azpgOUHTdECEt0lMRjcfYA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_tEdplloxdU6KCwmgb4fyJA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_PayPD_ALdEOed67ODqvUTg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_9J3X4NcKP0CpSjMwj-YE9g_2_0">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Tc_treu-9EBaUOlF0Ppi6bRAw_2_2">MMSI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_m62SUmRUn0KBfHej8fMFmA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_28_2025_To_1_28_2025_GJ23RJ3xJ0iqJKYeIieiGQ"
      id="Narr_EvQDkj3Z2U25CwoH3ne6wA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
